Agennix AG Reports Financial Results for Second Quarter and First Half of 2012
7/31/2012 9:16:30 AM
More...
|
Stem Cell Innovations to Provide Research and Assay Services to Agennix Inc.
3/2/2010 9:10:02 AM
More...
|
Agennix Inc. Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally
1/21/2010 10:58:56 AM
More...
|
GPC Biotech AG (GPCG.DE) Provides Update on Merger with Agennix Inc.
10/8/2009 10:15:19 AM
More...
|
Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
5/19/2009 7:24:50 AM
More...
|
GPC Biotech AG (GPCG.DE) and Agennix Announce Proposed Merger
2/18/2009 7:46:36 AM
More...
|
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4/22/2008 8:20:45 AM
More...
|
Agennix's Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer
2/26/2008 6:34:34 AM
More...
|
Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer Trial
1/17/2008 6:33:57 AM
More...
|
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
6/4/2007 11:30:08 AM
More...
|
|